Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp6 | Acromegaly | ECE2018

IGF-I response to pasireotide LAR treatment in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

Muhammad Ammar , Coopmans Eva , Gatto Federico , Franck Sanne , Janssen Joseph , van der Lelij Aart Jan , Hofland Leo , Neggers Sebastian

Background: The response to first-generation long-acting somatostatin analogues (LA-SSA) treatment in acromegaly depends on the expression of the somatostatin receptor (SSTR) subtypes. In contrast to octreotide and lanreotide which preferentially bind to SSTR2, pasireotide targets multiple SSTRs, with the highest binding affinity for SSTR5. It has previously been suggested that SSTR5 expression could predict the response to pasireotide LAR (PAS-LAR) treatment in acromegaly.</p...

ea0073oc12.2 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Improved glucose metabolism and decreased weight gain in leptin-resistant, IGFBP2-deficient, db/db mice induced by AZP-3404, a 9-amino acid analog of IGFBP2

Culler Michael D. , Milano Stéphane , Ovize Michel , Delale Thomas , van der Lelij Aart Jan , Clemmons David

Insulin-like growth factor binding protein-2 (IGFBP2) has been demonstrated to be a key mediator of the peripheral actions of leptin, and its deficiency is associated with impaired metabolic function. The metabolic activity of IGFBP2 can be localized to a unique heparin-binding domain (HBD-1) within its structure. AZP-3404 is a 9-amino acid analog of the IGFBP2 HBD-1 that has been demonstrated to increase glucose uptake by differentiated mouse myotubes in vitro, and to increas...